While many CH drivers exhibit similar frequency of truncating mutations across both CH and myeloid cancer cases, in some, a clear enrichment (TET2, PPM1D) or depletion (NOTCH1, ARID2) of truncating mutations is observed across CH (Fig. 3d). Here, TET2 is linked to cyclic hematopoiesis.